

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12P 21/00, 21/08, C12N 15/63, 1/11, 1/19, 1/21, 5/10, C07K 16/00, A61K 38/43, 39/00, C07K 14/245, 14/39, 14/435	A3	(11) International Publication Number: WO 99/41404 (43) International Publication Date: 19 August 1999 (19.08.99)
(21) International Application Number: PCT/EP99/00945 (22) International Filing Date: 12 February 1999 (12.02.99) (30) Priority Data: 98102546.3 13 February 1998 (13.02.98) EP (71) Applicant (for all designated States except US): MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN [DE/DE]; Berlin (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): GOODY, Roger, S. [GB/DE]; Hamackstrasse 61b, D-44139 Dortmund (DE). KONRAD, Manfred [DE/DE]; Zur Scharfmühle 74, D-37083 Göttingen (DE). LAVIE, Arnon [DE/DE]; Hamackstrasse 61, D-44139 Dortmund (DE). REINSTEIN, Joachim [DE/DE]; Plauener Strasse 54, D-44139 Dortmund (DE). SCHLICHTING, Ilme [DE/DE]; Redtenbacher Strasse 30, D-44139 Dortmund (DE). (74) Agent: VOSSIUS & PARTNER; Postfach 86 07 67, D-81634 München (DE).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> (88) Date of publication of the international search report: 28 October 1999 (28.10.99)
(54) Title: NOVEL MEANS AND METHODS FOR THE PREPARATION AND ACTIVATION OF NUCLEOSIDE AND NUCLEOTIDE BASED DRUGS		
(57) Abstract <p>Described are novel means and methods for the preparation and activation of nucleoside and nucleotide based drugs. In particular, a method for the production of a polypeptide having or having enhanced kinase activity for a nucleoside or nucleotide analog is provided and polypeptides obtainable by said method. Described are also polynucleotides and vectors encoding said polypeptide obtainable by the method of the invention as well as to host cells transformed therewith. Furthermore, antibodies against said polypeptide are provided and pharmaceutical and diagnostic compositions as well as kits comprising proteins having kinase activity for a nucleoside or nucleotide analog or their encoding polynucleotides or vectors. Furthermore, the use of the before described proteins, polypeptides, polynucleotides, vectors and antibodies is provided for the preparation of pharmaceutical compositions for treating, preventing and/or delaying a disease related to viral infection or cancer. In addition, a method for identifying inhibitors of nucleoside or nucleotide kinases is described and methods for identifying nucleoside or nucleotide based prodrugs employing the above mentioned polypeptides, polynucleotides, vectors and host cells. Also provided are compounds identifiable by said methods as well as pharmaceutical and diagnostic compositions comprising said inhibitors. Moreover, the use of proteins and polypeptides having nucleoside or nucleotide kinase activity or their encoding polynucleotides or vectors is described for the preparation of nucleoside or nucleotide phosphates or analogs and derivatives thereof.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/00945

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12P21/00 C12P21/08 C12N15/63 C12N1/11 C12N1/19
C12N1/21 C12N5/10 C07K16/00 A61K38/43 A61K39/00
C07K14/245 C07K14/39 C07K14/435

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12P C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	A. LAVIE ET AL.: "Structural basis for the efficient phosphorylation of 3'-azidothymidine monophosphate by E. coli thymidylate kinase" PROCEEDINGS OF NATIONAL ACADEMY OF SCIENCES USA, vol. 95, 1998, pages 14045-14050, XP002111243 *see the whole article* --- -/--	1-38

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

4 August 1999

Date of mailing of the international search report

25/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Marie, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/00945

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>A. LAVIE ET AL.: "Crystal structure of yeast thymidylate kinase complexed with the bisubstrate inhibitor TP5A at 2.0 Å resolution: implications for catalysis and AZT activation"</p> <p>BIOCHEMISTRY, vol. 37, 1998, pages 3677-3686, XP002111244 *see the whole article*</p>	1-38
Y	<p>A. LAVIE ET AL.: "Structure of thymidylate kinase reveals the cause behind the limiting step in AZT activation"</p> <p>NATURE STRUCTURE BIOLOGY, vol. 4, no. 8, 1997, pages 601-604, XP002111245 *see the whole article*</p>	1-38
Y	<p>D. HAZUDA ET AL.: "Failure of AZT: molecular perspective"</p> <p>NATURE MEDICINE, vol. 3, no. 8, 1997, pages 836-837, XP002111246 *see the whole article*</p>	1-38